A study presented at EADV in Paris today showed that dupilumab met its primary endpoints in a phase three study of adolescents with moderate-to-severe atopic dermatitis.
Topical vitamin A provides no benefit in treating atopic dermatitis, whereas topical vitamin D may actually exacerbate symptoms, according to an evidence-based review.
The biologic dupilumab is projected to be a cost-effective treatment for moderate-to-severe atopic dermatitis, shows a new study. (©Dzm1try/Shutterstock.com)
New research examined the potential role of Gram-negative skin bacteria in the pathogenesis and exacerbation of eczema, and their effectiveness to treat it.
A summary of treatments for atopic dermatitis in children.
Physicians spell out knowns and unknowns associated with treating pediatric atopic dermatitis.
Study shows that blocking IL-13 improves atopic dermatitis ― a promising finding for IL-13 atopic dermatitis drugs in development.
Patients with moderate-severe atopic dermatitis are at high risk of having inadequate disease control, according to a cross-sectional study in JAMA Dermatology.
Study finds the combination of duplilumab and topical corticosteroids works in hard-to-treat atopic dermatitis cases in adult patients.
FDA approves early, pre-approval trials for pediatric cases